Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Acoziborole - Drugs for Neglected Diseases Initiative Foundation

Next Previous
Drug Profile

Acoziborole - Drugs for Neglected Diseases Initiative Foundation

Alternative Names: AN-5568; Oxaborole SCYX-7158; SCYX-7158

Latest Information Update: 13 Apr 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Anacor Pharmaceuticals; SCYNEXIS
  • Developer Drugs for Neglected Diseases Initiative Foundation
  • Class Antiprotozoals; Benzamides; Organic boron compounds; Small molecules
  • Mechanism of Action Protein biosynthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III African trypanosomiasis

Most Recent Events

  • 08 Apr 2024 Drugs for Neglected Diseases plans a phase III trial for African trypanosomiasis (In adolescents, In adults, In the elderly) (PO, Tablets) (NCT06356974),
  • 03 May 2023 Drugs for Neglected Diseases completes phase-I trial in African trypanosomiasis (In volunteers, In adults) in Malaysia (PO) (NCT05947604)
  • 09 Feb 2023 Phase-I clinical trials in African trypanosomiasis (In volunteers, In adults) in Malaysia (PO) (NCT05947604) 700365758

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top